Market Signal Briefing

Archer Aviation is working toward the launch of an air taxi as well as an air taxi service. The company's vertical-lift aircraft is steadily working toward the approvals necessary for commercial use.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

HomeDividends AnalysisDividend Quick Picks

SummaryThe Dividend Growth Trifecta—quality, yield, and growth—remains my core focus for portfolio construction in an expensive market.Industry leaders like Ares Management Corporation and Blackstone Inc. offer superior risk-adjusted returns; I prefer buying dips in top names over chasing value in lower-quality peers.Schwab U.S. Dividend Equity ETF™ is off my buy list due to sector reconstitution and dimmed double-digit dividend growth prospects, despite holding a large position.My current buy list emphasizes REITs, utilities, and consumer staples for their blend of quality, yield, and growth. IvelinRadkov/iStock via Getty Images

Think of a Venn diagram with three circles overlapping in the middle.

One circle is Quality. Another is Yield. The last is Growth (specifically dividend growth). The overlap in the middle is what I like to call the "Dividend Growth

Analyst’s Disclosure:I/we have a beneficial long position in the shares of ARES, BX, SCHD, DGRW, NEE, CWEN.A, AMH, AMT, ARTNA, CDL either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Analyst’s Disclosure:I/we have a beneficial long position in the shares of SLVR either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

HomeEarnings AnalysisConsumer 

SummarySally Beauty Holdings delivered better-than-expected Q4 results, with sales, comps, margins, and earnings all exceeding consensus and internal expectations.SBH's operational improvements include 1.3% sales and comp growth, gross margin expansion to 52.2%, and adjusted EPS up 10% year-over-year.Balance sheet strength improved with $149M in cash, no revolver borrowings, net leverage down to 1.6x, and active debt repayment and share buybacks.At ~$16 per share, SBH trades at under 8x forward EPS; modest growth guidance supports taking profits but holding a small house position.Consider ringing the register on 50%+ gains and letting a bit of profit run. Alida Garcia/iStock via Getty Images

Today we are following up on Sally Beauty Holdings, Inc. (SBH). This is a stock we have held a small house position in. What is a house position? This is something we teach at

Analyst’s Disclosure:I/we have a beneficial long position in the shares of SBH either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

The carbon-capture story reveals the nation's shifting priorities and inconsistent approach to clean-energy and climate change.

SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced growing interventional use of its clonoSEQ® test among the 90 abstracts featuring clonoSEQ data at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place Dec. 6–9, 2025, in Orlando. Notably, 17 abstracts utilizing Adaptive’s clonoSEQ® test exemplify how next-generation sequencing-based measurable residual disease (MRD) status is guiding clinical actions to improve blood cancer patient care.

Practice-changing data from the phase II EndRAD study support the use of NGS MRD status prior to allogeneic hematopoietic cell transplantation (HCT) to guide the selection of non-total body irradiation (TBI) conditioning approaches to reduce long-term toxicities in children and young adults with B-cell acute lymphoblastic leukemia (B-ALL), without compromising outcomes. The study showed outstanding event-free and overall survival outcomes in 51 patients who were NGS MRD negative and received a non-TBI regimen. The study also enrolled a comparator cohort who received TBI and showed equivalent survival in NGS MRD negative patients who received TBI (the current standard of care) compared to non-TBI approaches (oral presentation, abstract 163).

“For young people facing leukemia, the impact of treatment doesn’t end when therapy does,” said Michael Pulsipher, M.D., Division Chief of Hematology, Oncology and Bone Marrow Transplantation at Primary Children’s Hospital and Huntsman Cancer Institute at the University of Utah. “The EndRAD results demonstrate that, for NGS MRD-negative patients, we may be able to choose transplant approaches without radiation that support both survival and long-term well-being—an advancement with real, lasting impact for patients and their families.”

Across hematologic malignancies, clonoSEQ MRD status is used by health care providers as an interventional tool to guide clinical decisions at key points in care. The presentations below show how investigators are applying clonoSEQ MRD results to tailor treatment intensity or duration with greater precision.

Multiple Myeloma (MM)

A total of 32 abstracts will be presented (31 MM, one smoldering MM), with a focus on MRD assessment of treatment response, real-world data demonstrating the link between MRD status and clinical outcomes, and several studies describing how clonoSEQ MRD results are being used to guide treatment decisions.A presentation focused on MRD dynamics in the phase III AURIGA study of 200 newly diagnosed MM patients demonstrated that deep MRD responses and sustained MRD negativity correlated with improved progression free survival. The study shows that use of intensified maintenance in MRD-positive patients post-transplant doubled MRD negativity rates (oral presentation, abstract 97). Non-Hodgkin Lymphoma (NHL)

Fifteen abstracts in NHL will be presented, focusing on use of MRD to better understand depth of response and to guide therapy.In diffuse large B-cell lymphoma (DLBCL), results from a phase II Wisconsin Oncology Network study which used clonoSEQ to de-escalate therapy in frail older adults with DLBCL will be presented (poster presentation, abstract 1964). Additionally, data supporting the integration of ctDNA into post–CAR T surveillance will be presented (oral presentation, abstract 941).Results from a phase II, MRD-guided study in older mantle cell lymphoma (MCL) patients demonstrate the use of clonoSEQ to guide duration of frontline BOVen therapy (zanubrutinib, obinutuzumab, venetoclax) (oral presentation, abstract 888).
Chronic Lymphocytic Leukemia (CLL)

Seven abstracts utilizing clonoSEQ MRD will be presented, with the majority leveraging the test to assess treatment response and guide treatment discontinuation.Data from a Phase II study of 80 patients with previously untreated CLL showed that time-limited pirtobrutinib, venetoclax, and obinutuzumab (PVO) achieved notably deep and durable remissions based on MRD assessment at a threshold of 10-6. MRD positive status using clonoSEQ was used to identify patients who may continue therapy, highlighting clonoSEQ as a potential tool for guiding treatment duration in this regimen (oral presentation, abstract 680). Acute Lymphoblastic Leukemia (ALL)

In addition to the EndRAD trial, 30 ALL abstracts will be presented describing the use of clonoSEQ to assess treatment response in investigator studies and real-world data, as well as analyses describing comparisons of bone marrow and peripheral blood MRD by clonoSEQ.
“The unprecedented volume and diversity of data at ASH this year further solidifies clonoSEQ’s leadership in the field of blood cancer MRD monitoring,” said Susan Bobulsky, chief commercial officer, MRD, Adaptive Biotechnologies. “Our unmatched body of clinical evidence and real-world patient experience, together with meaningful updates across lymphoid cancer clinical practice guidelines over the past year, reflect clear recognition of the test’s value in accelerating therapeutic progress and strengthening MRD-informed patient management.”

About clonoSEQ®
clonoSEQ® is the first and only FDA-cleared in vitro diagnostic (IVD) test for detecting and tracking minimal (or measurable) residual disease (MRD) in patients with multiple myeloma (MM) or B-cell acute lymphoblastic leukemia (B-ALL) using bone marrow, and in patients with chronic lymphocytic leukemia (CLL) using blood or bone marrow. clonoSEQ is also available in diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and other lymphoid cancers and specimen types as a CLIA-validated laboratory developed test (LDT). clonoSEQ is covered by Medicare for MM, CLL, ALL, DLBCL and MCL.

clonoSEQ identifies and quantifies DNA sequences in malignant cells—detecting one cancer cell in one million healthy cells—to help clinicians and researchers assess and monitor MRD with precision over time. It delivers standardized, sensitive results that inform treatment decisions, predict outcomes, and detect relapses earlier.

clonoSEQ is CE-marked under the EU In Vitro Diagnostic Regulation (IVDR). For intended use details in the EU, see the instructions for use, available on request. To review the FDA-cleared uses of clonoSEQ, visit clonoSEQ.com/technical-summary.

About Adaptive Biotechnologies
Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business areas: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer and autoimmune disorders. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.

Forward Looking Statements
This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.

In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations
201-396-1687
[email protected]

ADAPTIVE MEDIA
Erica Jones, Associate Director, Corporate Communications
206-279-2423
[email protected]

Analyst’s Disclosure:I/we have a beneficial long position in the shares of TSM either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

NEW YORK, Dec. 06, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of StubHub Holdings, Inc. (NYSE: STUB) pursuant and/or traceable to the Registration Statement issued in connection with StubHub’s September 2025 initial public offering (the “IPO”), of the important January 23, 2026 lead plaintiff deadline.

SO WHAT: If you purchased StubHub common stock you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the StubHub class action, go to https://rosenlegal.com/submit-form/?case_id=48412 or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 23, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit,  the Registration Statement was materially false and misleading and omitted to state that: (1) StubHub was experiencing changes in the timing of payments to vendors; (2) those changes had a significant adverse impact on free cash flow, including trailing twelve months (“TTM”) free cash flow; (3) as a result, StubHub’s free cash flow reports were materially misleading, and that; (4) as a result of the foregoing, defendants’ positive statements about StubHub’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the StubHub class action, go to https://rosenlegal.com/submit-form/?case_id=48412 or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

This is the second capital raise in 6 months.

In this video, I will cover recent updates regarding SoFi Technologies (SOFI 6.15%). Watch the short video to learn more, consider subscribing, and click the special offer link below.

*Stock prices used were from the trading day of Dec. 4, 2025. The video was published on Dec. 5, 2025.

Neil Rozenbaum has positions in SoFi Technologies. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Neil is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool.

Investors are hopeful of another good year in 2026.

The streaming audio company has gained significant adoption from consumers worldwide.

*Stock prices used were the afternoon prices of Dec. 1, 2025. The video was published on Dec. 3, 2025.

Parkev Tatevosian, CFA has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Spotify Technology. The Motley Fool has a disclosure policy. Parkev Tatevosian is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool.

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with seve.

Italy's market regulator has found no evidence of a secret agreement involving Monte dei Paschi di Siena and some of its shareholders to gain control of Mediobanca and insurer Generali, Il Sole-24 Ore reported on Saturday.

Surprisingly, DoorDash has sustained premium revenue growth.

DoorDash (DASH +1.73%) has demonstrated that consumers are willing to pay for convenience.

*Stock prices used were the afternoon prices of Dec. 3, 2025. The video was published on Dec. 5, 2025.

Parkev Tatevosian, CFA has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends DoorDash. The Motley Fool has a disclosure policy. Parkev Tatevosian is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool.

HomeStock IdeasLong IdeasTech 

SummaryOracle is reiterated as a buy, with expectations that its recent highs will be exceeded as OCI drives substantial revenue growth.OCI's superior performance, cost advantages, and hybrid/multi-cloud architecture are fueling rapid market share gains and underpin long-term forecasts.Customer concentration risk with OpenAI is acknowledged, but capital-raising and execution risks are deemed manageable given Oracle's positioning.Oracle's business model transformation to cloud infrastructure is creating valuation dislocations, offering a compelling entry point amid negative sentiment. Mesut Dogan/iStock Editorial via Getty Images

From Riches to Rags in 3 months Healthy skepticism is the stock-in-trade of analysts and investors. That is particularly true in the tech space. Many dreams don’t get realized or get realized in a far

Analyst’s Disclosure:I/we have a beneficial long position in the shares of ORCL either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Quick Insights

Recommended For You

December 06, 2025 7:18 AM EST | Source: Bleichmar Fonti & Auld
New York, New York--(Newsfile Corp. - December 6, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Alexandria Real Estate Equities, Inc. (NYSE: ARE) and certain of the Company's senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws.

If you invested in Alexandria Real Estate, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/alexandria-real-estate-class-action-lawsuit.

Investors have until January 26, 2026, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Alexandria Real Estate securities. The case is pending in the U.S. District Court for the Central District of California and is captioned Hern v. Alexandria Real Estate Equities, Inc., et al., No. 2:25-cv- 11319.

Why is Alexandria Real Estate Being Sued for Securities Fraud?

Alexandria Real Estate is a real estate investment trust. Its tenants are concentrated in life science industries, such as pharmaceutical and biotechnology companies.

During the relevant period, Alexandria Real Estate touted its leasing volume and development pipeline, specifically regarding a property in Long Island City, New York, stating that leasing volume was "solid" and its pipeline was "well positioned to capture future demand when expansion needs arise."

As alleged, in truth, Alexandria Real Estate was experiencing lower occupancy rates and slower leasing activity such that it was required to take a real estate impairment charge of $323.9 million with $206 million attributed to its Long Island City property.

Why did Alexandria Real Estate's Stock Drop?

On October 27, 2025, Alexandria Real Estate announced results below expectations for 3Q 2025 and cut guidance for the remainder of the fiscal year. The company attributed the results to lower occupancy rates and slower leasing activity. It also announced a real estate impairment charge of $323.9 million with $206 million attributed to its Long Island City property, stating that the property was not a life science destination that could scale. Alexandria Real Estate also announced additional impairment charges that may be recognized in 4Q 25 ranging from $0 to $685 million. This news caused the price of Alexandria Real Estate stock to drop $14.93 per share, or more than 19%, from a closing price of $77.87 per share on October 27, 2025, to $62.94 per share on October 28, 2025.

Click here for more information: https://www.bfalaw.com/cases/alexandria-real-estate-class-action-lawsuit.

What Can You Do?

If you invested in Alexandria Real Estate you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/alexandria-real-estate-class-action-lawsuit

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named "Elite Trial Lawyers" by the National Law Journal, among the top "500 Leading Plaintiff Financial Lawyers" by Lawdragon, "Titans of the Plaintiffs' Bar" by Law360 and "SuperLawyers" by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/alexandria-real-estate-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/276826

December 06, 2025 7:18 AM EST | Source: Bleichmar Fonti & Auld
New York, New York--(Newsfile Corp. - December 6, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company's senior executives for potential violations of the federal securities laws.

If you invested in MoonLake, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/moonlake-immunotherapeutics-class-action-lawsuit.

Investors have until December 15, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in MoonLake common stock. The case is pending in the U.S. District Court for the Southern District of New York and is captioned Peters v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08612.

Why Was MoonLake Sued for Securities Fraud?

MoonLake is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases. During the relevant period, MoonLake conducted highly anticipated Phase 3 VELA trials for sonelokimab ("SLK"), an investigational therapeutic designed to treat adult participants with moderate to severe hidradenitis suppurativa ("HS").

MoonLake told investors that its "strong clinical data," including results from its Phase 2 MIRA trial, translate into "higher clinical responses for patients, and provide ample opportunity for differentiation of sonelokimab versus all competitors." The Company also stated that SLK's Nanobody structure differed in beneficial ways from traditional monoclonal antibody treatments from its competitors.

As alleged, in truth, the Company's clinical data and Nanobody structure did not confer a superior clinical benefit over its competitors, calling into question the drug's chances for regulatory approval and commercial viability.

The Stock Declines as the Truth Is Revealed

On September 28, 2025, MoonLake reported its week 16 results of the VELA Phase 3 trials. The Company reported disappointing results for both trials, with VELA-2 failing to meet its primary endpoint, calling into question the drug's chances for regulatory approval and commercial viability. On this news, the price of MoonLake stock fell $55.75 per share, or nearly 90%, from $61.99 per share on September 26, 2025, to $6.24 per share on September 29, 2025, the following trading day.

Click here for more information: https://www.bfalaw.com/cases/moonlake-immunotherapeutics-class-action-lawsuit.

What Can You Do?

If you invested in MoonLake you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/moonlake-immunotherapeutics-class-action-lawsuit

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named "Elite Trial Lawyers" by the National Law Journal, among the top "500 Leading Plaintiff Financial Lawyers" by Lawdragon, "Titans of the Plaintiffs' Bar" by Law360 and "SuperLawyers" by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/moonlake-immunotherapeutics-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/276836

December 06, 2025 7:18 AM EST | Source: Bleichmar Fonti & Auld
New York, New York--(Newsfile Corp. - December 6, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) and certain of the Company's senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws.

If you invested in Inspire, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/inspire-medical-systems-inc-class-action-lawsuit.

Investors have until January 5, 2026, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Inspire stock. The case is pending in the U.S. District Court for the District of Minnesota and is captioned City of Pontiac Reestablished General Employees' Retirement System v. Inspire Medical Systems, Inc., et al., No. 0:25-cv-04247.

Why is Inspire Being Sued for Securities Fraud?

Inspire develops and manufactures an implantable medical device for the treatment of sleep apnea. The latest version of the device is the Inspire V. The company announced FDA approval of Inspire V on August 2, 2024.

During the relevant period, Inspire repeatedly assured investors that it had taken all necessary steps to facilitate the launch of Inspire V and that it would launch the device as soon as sufficient inventory was available to meet supposedly high demand.

As alleged, in truth, Inspire failed to take basic steps to prepare clinicians and payors for the rollout, resulting in significant delays in adoption of the device. Moreover, the launch suffered from weak demand, as many customers already had excess inventory of the company's older devices.

Why did Inspire's Stock Drop?

On August 4, 2025, Inspire disclosed that the Inspire V launch was facing an "elongated timeframe" and as a result, it was reducing its 2025 earnings per share guidance by more than 80%. The company attributed the longer timeframe to a number of previously undisclosed factors including that many implanting centers "did not complete the training, contracting and onboarding required prior to the purchase and implant of Inspire V," that certain "software updates for claims submissions and processing did not take effect until July 1, [2025]" which meant implanting centers could not bill for procedures until that date, and that demand for the Inspire V was poor because Inspire's customers had a backlog of older versions of the company's device.

On this news, the price of Inspire stock dropped $42.04 per share, or more than 32%, from $129.95 per share on August 4, 2025, to $87.91 per share on August 5, 2025.

Click here for more information: https://www.bfalaw.com/cases/inspire-medical-systems-inc-class-action-lawsuit.

What Can You Do?

If you invested in Inspire you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/inspire-medical-systems-inc-class-action-lawsuit

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named "Elite Trial Lawyers" by the National Law Journal, among the top "500 Leading Plaintiff Financial Lawyers" by Lawdragon, "Titans of the Plaintiffs' Bar" by Law360 and "SuperLawyers" by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/inspire-medical-systems-inc-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/276830

December 06, 2025 7:18 AM EST | Source: Bleichmar Fonti & Auld
New York, New York--(Newsfile Corp. - December 6, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against James Hardie Industries plc (NYSE: JHX) and certain of the Company's senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws.

If you invested in James Hardie, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/james-hardie-industries-class-action-lawsuit.

Investors have until December 23, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in James Hardie common stock (formerly American Depositary Shares). The class action is pending in the U.S. District Court for the Northern District of Illinois and is captioned Laborers' District Council and Contractors' Pension Fund of Ohio v. James Hardie Industries plc, et al., No. 1:25-cv-13018.

Why Was James Hardie Sued for Securities Fraud?

James Hardie is a producer and marketer of high-performance fiber cement building solutions. The largest application for the Company's fiber cement building products in the United Stated and Canada is in external siding for the residential building industry.

During the relevant period, James Hardie told investors that the results of its North American fiber cement segment demonstrated its "inherent strength" and "the underlying momentum in our strategy." The Company also stated on May 20, 2025, that it was seeing "normal stock levels" among its customers and that it was "seeing performance in the month to date as we would expect."

As alleged, in truth, the Company's North American sales during the relevant period were the result of inventory loading by channel partners, with the hallmarks of fraudulent channel stuffing, not sustainable customer demand as represented.

The Stock Declines as the Truth Is Revealed

On August 19, 2025, James Hardie revealed that its North American fiber cement sales declined 12% during the quarter, driven by destocking first discovered "in April through May" as customers "made efforts to return to more normal inventory levels[.]" The Company also revealed that significant inventory destocking was expected to continue to impact sales for the next several quarters. On this news, the price of James Hardie stock fell $9.79 per share, or more than 34%, from $28.43 per share on August 19, 2025, to $18.64 per share on August 20, 2025.

On November 17, 2025, James Hardie announced that Rachel Wilson had decided to step down from her role as CFO.

Click here for more information: https://www.bfalaw.com/cases/james-hardie-industries-class-action-lawsuit.

What Can You Do?

If you invested in James Hardie you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/james-hardie-industries-class-action-lawsuit

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named "Elite Trial Lawyers" by the National Law Journal, among the top "500 Leading Plaintiff Financial Lawyers" by Lawdragon, "Titans of the Plaintiffs' Bar" by Law360 and "SuperLawyers" by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/james-hardie-industries-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/276832

December 06, 2025 7:18 AM EST | Source: Bleichmar Fonti & Auld
New York, New York--(Newsfile Corp. - December 6, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Stride, Inc. (NYSE: LRN) and certain of the Company's senior executives for securities fraud after significant stock drops resulting from the potential violations of the federal securities laws.

If you invested in Stride, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/stride-inc-class-action-lawsuit.

Investors have until January 12, 2026, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Stride securities. The case is pending in the U.S. District Court for the Eastern District of Virginia and is captioned MacMahon v. Stride, Inc., et al., No. 1:25-cv- 02019.

Why is Stride Being Sued for Securities Fraud?

Stride is an education technology company that provides an online platform to students throughout the U.S. During the relevant period, Stride stated it was seeing "increasing growth in our business," "in-year strength in demand" for its products and services, and that its customers and potential customers "continue to choose us in record numbers."

As alleged, in truth, Stride had inflated enrollment numbers by retaining "ghost students," ignored compliance requirements for its employees, and had "poor customer experience" that resulted in "higher withdrawal rates," "lower conversion rates," and had driven students away.

Why did Stride's Stock Drop?

On September 14, 2025, a report stated that a complaint had been filed against Stride for fraud, deceptive trade practices, systemic violations of law, and intentional and tortious misconduct. It claimed Stride inflated enrollment numbers by retaining "ghost students" on rolls to secure state funding and ignored compliance requirements, including background checks and licensure laws for its employees. This news caused the price of Stride stock to drop $18.60 per share, or more than 11%, from a closing price of $158.36 per share on September 12, 2025, to $139.76 per share on September 15, 2025.

Then, on October 28, 2025, Stride admitted that "poor customer experience" resulted in "higher withdrawal rates," "lower conversion rates," and drove students away. Stride estimated the impact caused approximately 10,000-15,000 fewer enrollments and stated that, because of this, its outlook is "muted" compared to prior years. This news caused the price of Stride stock to drop $83.48 per share, or more than 54%, from a closing price of $153.53 per share on October 28, 2025, to $70.05 per share on October 29, 2025.

Click here for more information: https://www.bfalaw.com/cases/stride-inc-class-action-lawsuit.

What Can You Do?

If you invested in Stride you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/stride-inc-class-action-lawsuit

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named "Elite Trial Lawyers" by the National Law Journal, among the top "500 Leading Plaintiff Financial Lawyers" by Lawdragon, "Titans of the Plaintiffs' Bar" by Law360 and "SuperLawyers" by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/stride-inc-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/276835

HomeStock IdeasLong IdeasFinancials 

SummaryAffirm is upgraded to a BUY, driven by robust top-line growth, disciplined credit quality, and expanding partnerships with major tech platforms.AFRM's proprietary credit models, adaptive checkout, and merchant tools have fueled a 30% YoY increase in active merchants and strong consumer growth.Despite concentration risk with top partners and regulatory uncertainties, AFRM's healthy loan portfolio and improving credit metrics underscore operational strength.Trading at 22.4x forward earnings with 78% projected EPS growth for FY26, AFRM's premium valuation is justified by its superior growth trajectory. hapabapa/iStock Editorial via Getty Images

Introduction: Affirm (AFRM) has continued to solidify its positioning within the global lending ecosystem through its advanced models and expanded partnerships with various titans of the tech industry.

While the company does face a

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in AFRM over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Quick Insights

Recommended For You

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Why Trust CoinGape

CoinGape has covered the cryptocurrency industry since 2017, aiming to provide informative insights to our readers. Our journal analysts bring years of experience in market analysis and blockchain technology to ensure factual accuracy and balanced reporting. By following our Editorial Policy, our writers verify every source, fact-check each story, rely on reputable sources, and attribute quotes and media correctly. We also follow a rigorous Review Methodology when evaluating exchanges and tools. From emerging blockchain projects and coin launches to industry events and technical developments, we cover all facets of the digital asset space with unwavering commitment to timely, relevant information.

Ethereum Price remains steady at $3,000 as the cryptocurrency market experiences a minor cooldown over the last 24 hours. ETH saw a 4% decline during this period, following a broader bearish trend in the market. 

The cryptocurrency fell below the mark of $3,100 support, which indicated the possibility of additional downward force. All in all, the crypto market has experienced a decrease of 3% and 10% in the last day and 30 days, respectively.

The Crypto Fear & Greed Index is at its lowest point of 21, which is a sign of high fear, and it causes certain liquidations. The slowdown is an embodiment of institutional drain, regulatory issues, and technical failures. Interestingly, Spot Bitcoin ETFs have experienced outflows of up to $2.7 billion since November of this year.

Bitmine Continues Aggressive Ethereum Purchases
Bitmine, which is headed by Tom Lee, has taken further cause in the cryptocurrency market, buying an additional 22,676 Ethereum (68.67 million) today. With this purchase, the total amount of Ethereum that Bitmine has bought is 64,622 ETH worth an eye-blowing $199.4 million, all in the last 24 hours.

The last transaction, which was registered only some hours ago involved 22,676 ETH moved out of the Hot Wallet of BitGo into the wallet of Bitmine.

🚨BITMINE KEEPS ON BUYING ETH!

Tom Lee’s Bitmine scooped up another 22,676 $ETH ($68.67M) today.

That brings total purchases to 64,622 $ETH ($199.4M) since yesterday. pic.twitter.com/eUYiY8YpEA

— Coin Bureau (@coinbureau) December 6, 2025

Since Ethereum price is oscillating, the aggressive approach of Bitmine proves that this company believes in the future of ETH. The fact that such a great number of Ethereum can be collected in such a short time underlines the leading position of Bitmine on the market.

Ethereum Price Prediction: Will $3,000 Hold or Drop to $2,800?
Cryptocurrency analysts provided an update on the Ether price move and stated that the token is holding steady above the $3,000 mark. Nonetheless, a drop in the price of Ethereum to a level lower than this critical value, the Ethereum may drop to the support zone of $2,800.

The analyst stressed that Ethereum is at a crucial point at the level of $3,000 when it comes to its price dynamics in the immediate future. The break is below, the traders ought to be keen on a possible fall to the level of $2,800, which is a major level of support.

$ETH is still holding above the $3,000 level.

If Ethereum breaks below this, it’ll drop towards the $2,800 zone. pic.twitter.com/ypYjZhnOoL

— Ted (@TedPillows) December 6, 2025

Key Levels To Watch
The ETH price hovered at $3,031 on Saturday, showing mixed signals as it continued to trade within a narrow range. The price could not break the most significant level of resistance of $3,100, and could not break the latest level of support of $3,300.

The Moving Average Convergence Divergence (MACD) indicated a bearish crossover. The MACD line went down the signal line, giving an indication of further downward movement.

The Relative Strength Index (RSI) is at 46, which is far below the 50 level. If the Ethereum long-range prediction manages to breach the $3,100 mark, it could retest the $3,300 resistance. 

Source: ETH/USD 4-hour chart: Tradingview
On the other hand, a continued dip below $3,000 may push the price further down, opening the door for potential bearish targets in the coming days.

Frequently Asked Questions (FAQs)

Ethereum's price has been affected by broader market bearish trends, institutional outflows, regulatory concerns, and technical breakdowns.

Bitmine, led by Tom Lee, has made a significant investment in Ethereum, purchasing $199 million worth of ETH, signaling confidence in its long-term potential.

Investment disclaimer: The content reflects the author’s personal views and current market conditions. Please conduct your own research before investing in cryptocurrencies, as neither the author nor the publication is responsible for any financial losses.

Ad Disclosure: This site may feature sponsored content and affiliate links. All advertisements are clearly labeled, and ad partners have no influence over our editorial content.

/

Bitcoin Hyper Presale Review: How Utility is Unlocked With ZK-SVM Rollup
Morgan Stanley Turns Bullish, Says Fed Will Cut Rates by 25bps This Month
ETF Expert Nate Geraci Says Bitcoin Still Lacks Proof of Digital Gold Status
Pi Network Update: Team Launches AI Tools to Boost KYC and Mainnet Migration for Investors
U.S. SEC’s Crypto Task Force Sets Dec. 15 for Privacy Roundtable After Previous Delay

Ethereum Price Holds $3,000 as Bitmine Scoops Up $199M in ETH; What Next?

Solana Price Outlook Strengthens as Spot ETFs See $15.68M in Fresh Inflows

Dogecoin Price Gears Up for a $0.20 Breakout as Inverse H&S Takes Shape

Bitcoin Price Forecast as BlackRock Sends $125M in BTC to Coinbase — Is a Crash Inevitable?

XRP Price Prediction As Spot ETF Inflows Near $1 Billion: What’s Next?

Solana Price Outlook: Reversal at Key Support Could Lead to $150 Target

Pi Network continues to struggle for momentum even as major cryptocurrencies rebound. While Bitcoin has climbed back above $94,000 and Ethereum has moved beyond $3,200 in early December, PI has gone in the opposite direction. The token is down about 12% this week and is trading slightly above $0.22, highlighting weak sentiment in the short term.

But behind the scenes, the Pi team is rolling out one of its most significant upgrades yet—an improvement they believe will finally ease verification delays and help millions move toward Mainnet.

Pi Network AI Upgrade Cuts KYC Delays To help users who are stuck in the verification queue, Pi Network has revamped its KYC system with new AI-powered tools. According to the team, these updates have reduced pending manual reviews by 50%, speeding up the process for users trying to become Mainnet-ready.

The upgrade relies on the same automated technology used in Fast Track KYC, introduced in September to help new users set up Mainnet wallets without completing 30 mining sessions. Fast Track is no longer a separate shortcut; it is now fully merged into the Standard KYC process, creating a simpler and more consistent verification flow.

This change comes at a crucial time for the project.

Pi Token Unlock December Pi Network is preparing for a December unlock of 190 million tokens—worth more than $40 million at current prices. With millions still waiting for verification, the team is trying to avoid potential congestion during one of its biggest events of the year.

The latest AI upgrades also make the verification system flexible enough for future use. Apps built within the Pi ecosystem may eventually rely on Pi’s human-verified identity layer, giving the KYC system broader utility beyond Mainnet migration.

Progress on Validator Rewards and a Growing EcosystemThe Pi team also announced progress on long-awaited validator rewards, which are expected to go live by the end of Q1 2026. The delay is due to the massive amount of network data collected since 2021 that still needs to be processed.

So far, 17.5 million users have passed KYC and 15.7 million have reached Mainnet. Around 3 million users still need to complete additional steps, and the team is encouraging them to finish soon.

In addition to technical upgrades, Pi Network has recently entered the EU’s MiCA regulatory framework, giving it a stronger foothold in Europe. It has also partnered with CiDi Games to integrate Pi into Web3 gaming experiences, creating more ways for Pioneers to engage with the ecosystem.

Despite the recent price decline, Pi Network is moving through one of its most important growth phases, and the December unlock will test how prepared the project truly is.

Never Miss a Beat in the Crypto World!Stay ahead with breaking news, expert analysis, and real-time updates on the latest trends in Bitcoin, altcoins, DeFi, NFTs, and more.

FAQsHow does Pi Network’s AI KYC upgrade work?

The AI KYC system reduces pending manual reviews by 50%, speeding up verification and making it easier to reach Mainnet.

What happens to my mined PI if I miss the December 2025 token unlock deadline?

Nothing bad—your balance stays safe forever. You just can’t transfer or sell it until you finish KYC and migrate to Mainnet. The unlock only adds new tokens to circulation; it doesn’t burn un-migrated coins.

Why does Pi Coin have almost no trading volume compared to other altcoins?

Because 95%+ of the supply is still locked behind KYC and Mainnet migration. Real liquid supply is tiny right now—once the remaining 30–40 million users migrate in 2026, daily volume could explode overnight.

If I finish KYC today, how long until I actually get my coins on Mainnet in December 2025?

With the new AI upgrade, most new KYC submissions are clearing in 3–14 days (sometimes same day). If you pass before mid-December, you’ll very likely receive your full balance before or during the 190 million token unlock.

Trust with CoinPedia:CoinPedia has been delivering accurate and timely cryptocurrency and blockchain updates since 2017. All content is created by our expert panel of analysts and journalists, following strict Editorial Guidelines based on E-E-A-T (Experience, Expertise, Authoritativeness, Trustworthiness). Every article is fact-checked against reputable sources to ensure accuracy, transparency, and reliability. Our review policy guarantees unbiased evaluations when recommending exchanges, platforms, or tools. We strive to provide timely updates about everything crypto & blockchain, right from startups to industry majors.

Investment Disclaimer:All opinions and insights shared represent the author's own views on current market conditions. Please do your own research before making investment decisions. Neither the writer nor the publication assumes responsibility for your financial choices.

Sponsored and Advertisements:Sponsored content and affiliate links may appear on our site. Advertisements are marked clearly, and our editorial content remains entirely independent from our ad partners.

Sat, 6/12/2025 - 10:48

XRP ETFs have established a position among the fastest-growing crypto-asset vehicles, surpassing the $1 billion milestone in under a month.

Cover image via U.Today

Disclaimer: The opinions expressed by our writers are their own and do not represent the views of U.Today. The financial and market information provided on U.Today is intended for informational purposes only. U.Today is not liable for any financial losses incurred while trading cryptocurrencies. Conduct your own research by contacting financial experts before making any investment decisions. We believe that all content is accurate as of the date of publication, but certain offers mentioned may no longer be available.

Recent data suggest XRP ETFs are among the fastest-growing crypto-asset vehicles, surpassing the $1 billion milestone in under a month, indicating significant acceptance in traditional finance markets.

November saw a flood of XRP ETFs with Canary Capital, Franklin Templeton, Bitwise and Grayscale launching in the month. Amplify ETFs, which manages more than $16 billion in assets under management, also launched an XRP covered-call ETF, referred to as the first XRP-based option income ETF.

Rex Osprey XRP ETF (XRPR) launched earlier in September as the first U.S. listed XRP ETF, albeit under the 40 act wrapper.

HOT Stories

$1 billion reachedXPMarket, an XRP Ledger-based platform that tracks existing and upcoming spot and leveraged XRP ETFs, reveals the latest milestone achieved by XRP funds.

In a tweet, XPMarket stated that XRP ETFs have surpassed $1 billion in holdings in less than a month.

XPMarket tracks XRP spot ETFs, including Rex Osprey XRP ETF (XRPR), Bitwise XRP ETF (XRP), Canary XRP ETF (XRPC), Franklin XRP ETF (XRPZ), Grayscale XRP trust (GXRP) and Amplify XRP ETF (XRPM).

The platform also tracks leveraged XRP ETFs, including Teucrium 2x Long Daily XRP (XXRP), 2x XRP ETF (XRPT) and Volatility Shares XRP ETF (XRPI).

What's coming?XRP ETFs continue to attract inflows, sustaining their strong post-launch run. XRP funds, including those from Canary Capital, Grayscale, Bitwise and Franklin Templeton, accounted for a total net inflow of $897.35 million, according to SoSo data, indicating XRP's acceptance and liquidity in traditional finance markets.

XPMarkets says that the best part of XRP ETF growth is that these are only a fraction of funds that have gone live.

In the days ahead, 21Shares, CoinShares and WisdomTree are expected to roll out their own XRP exchange-traded funds.

XPMarkets noted that while BlackRock and Fidelity have launched BTC and ETH ETFs, these titans are yet to launch XRP ETFs, indicating vast potential ahead for XRP.

"XRP ETF engines seem to just be starting up whilst we wait for the titans to jump in," XPMarkets wrote.

Related articles